Compare KFRC & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | VSTM |
|---|---|---|
| Founded | 1962 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 470.7M |
| IPO Year | 1996 | 2011 |
| Metric | KFRC | VSTM |
|---|---|---|
| Price | $26.15 | $5.61 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $38.50 | $15.00 |
| AVG Volume (30 Days) | 271.6K | ★ 1.5M |
| Earning Date | 04-27-2026 | 03-04-2026 |
| Dividend Yield | ★ 6.19% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,329,007,000.00 | $30,914,000.00 |
| Revenue This Year | $2.78 | $254.18 |
| Revenue Next Year | $4.32 | $99.39 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $24.49 | $4.01 |
| 52 Week High | $50.14 | $11.25 |
| Indicator | KFRC | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 37.98 | 41.71 |
| Support Level | $25.01 | $5.56 |
| Resistance Level | $28.41 | $6.66 |
| Average True Range (ATR) | 1.13 | 0.37 |
| MACD | 0.16 | -0.01 |
| Stochastic Oscillator | 30.15 | 26.21 |
Kforce Inc is a solutions firm specializing in technology, finance, accounting, and other professional staffing services. The company operates two business segments: the Technology segment, which provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. The FA segment offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting, business and cost analysis; and taxation and treasury. The majority of revenue is earned through the Technology segment.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.